Fukushima M
Gan To Kagaku Ryoho. 1983 Sep;10(9):1930-5.
Prostaglandins (PGs) are bioregulatory substances and are widely distributed in a variety of tissues. Numerous facts have been described in relation to cancer biology with PGs. The purpose of our study lies in the creation of anti-tumor PGs. We have described that PGD2 has strong cell growth inhibitory activity; furthermore, we discovered that PGJ2, 9-deoxy-delta 9-PGD2, has 3 times stronger activity than the mother compound, PGD2. In vivo experiments showed that only PGA2 and PGJ2 exert antitumor activity. Thus, cyclopentenone ring structure in PG seems to be an essential moiety for cytotoxicity of PG. On the basis of the above facts, we propose tha name of antineoplastic PGs for PGA and PGJ derivatives which have cyclopentenone ring. Recently, we developed several antineoplastic PGs which showed IC50 value less than 0.3 microgram/ml against L1210 leukemia cells, and these compounds also showed antitumor activity against Ehrlich ascites tumor in vivo comparable to that of cyclophosphamide. The action mechanism seems to be in its alkylation activity of the cyclopentenone structure and not in receptor-cAMP route. Spectrum of anti-tumor activity and its toxicity in vivo are now under investigation. In this brief review, mainly our recent approaches in this field are discussed.
前列腺素(PGs)是生物调节物质,广泛分布于多种组织中。关于PGs与癌症生物学的关系,已有大量事实被描述。我们研究的目的在于创制抗肿瘤PGs。我们已描述过,前列腺素D2(PGD2)具有很强的细胞生长抑制活性;此外,我们还发现,前列腺素J2(PGJ2),即9-脱氧-δ9-PGD2,其活性比母体化合物PGD2强3倍。体内实验表明,只有前列腺素A2(PGA2)和PGJ2具有抗肿瘤活性。因此,PG中的环戊烯酮环结构似乎是PG细胞毒性的必需部分。基于上述事实,我们提议将具有环戊烯酮环的PGA和PGJ衍生物命名为抗肿瘤PGs。最近,我们研制出了几种抗肿瘤PGs,它们对L1210白血病细胞的半数抑制浓度(IC50)值小于0.3微克/毫升,并且这些化合物在体内对艾氏腹水瘤也显示出与环磷酰胺相当的抗肿瘤活性。其作用机制似乎在于环戊烯酮结构的烷基化活性,而非受体-环磷酸腺苷(cAMP)途径。目前正在研究其抗肿瘤活性谱及其体内毒性。在这篇简短的综述中,主要讨论了我们在该领域最近的研究方法。